PCSK9 and cardiovascular disorder: Previous 2×2 factorial MR studies have identified combination therapies primarily within cardiovascular disease for PCSK9 and CETP inhibition, NPC1L1 and HMGCR inhibition, and IL-6 and PCSK9/CETP/NPC1L1 inhibition8,34,35.